Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition) by Roots Analysis

 

Several approved therapeutic products, which are currently available as intravenous dosage forms, are being reformulated and evaluated for subcutaneous administration. Further, many existing drug delivery devices, including prefilled syringes, pen injectors, autoinjectors, needle-free injectors and large volume wearable injectors, have been / are being designed for subcutaneous administration of biologics.

 

To order this 530+ page report, which features 160+ figures and 190+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

 

The USD 180+ billion (by 2030) financial opportunity associated with subcutaneous biologics, affiliated drug delivery systems and subcutaneous formulation technology licensing deals, has been analyzed across the following segments:

§  Phase of development

§  Approved

§  Pre-registration & Phase III

§  Phase II & Phase II/III

 

§  Type of molecule

§  Cell and gene therapies

§  Monoclonal antibodies

§  Proteins

§  Peptides (recombinant)

§  Vaccines

§  Others

 

§  Target therapeutic area

§  Autoimmune disorders

§  Blood disorders

§  Bone disorders

§  Genetic disorders

§  Metabolic disorders

§  Neurological disorders

§  Oncological disorders

§  Respiratory disorders

§  Others

 

§  Type of drug delivery system

§  Large volume wearable injectors

§  Autoinjectors

§  Prefilled syringes

§  Needle-free injectors

§  Drug reconstitution systems

 

To Request for sample - https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

 

§  Revenues from licensing deals

§  Upfront payments

§  Milestone payments

 

§  Key geographical regions

§  North America

§  Europe

§  Asia Pacific

§  Rest of the World

 

The Subcutaneous Biologics, Technologies and Drug Delivery Systems (3rd Edition), 2020-2030”report features the following companies, which we identified to be key players in this domain:

§  Adocia

§  Ajinomoto Bio-Pharma Services

§  Arecor

§  Alteogen

§  Ascendis Pharma

§  Avadel Pharmaceuticals

§  Camurus

§  Creative BioMart

§  Creative Biolabs

§  DURECT

§  Eagle Pharmaceuticals

§  Halozyme Therapeutics

§  MedinCell

§  Xeris Pharmaceuticals

§  Serina Therapeutics

 

Table of Contents

1.     Preface

 

2.     Executive Summary

 

3.     Introduction

 

4.     Subcutaneous Biologics: Current Market Landscape

 

5.     Case Study: Leading Subcutaneous Biologics

 

6.     Subcutaneous Formulation Technologies: Current Market Landscape

 

7.     Subcutaneous Formulation Technology Developers: Company Competitiveness Analysis

 

8.     Subcutaneous Formulation Technology Developers: Company Profiles

 

9.     Partnerships and Collaborations

 

10.  Subcutaneous Drug Delivery Systems: Current Market Landscape

 

11.  Swot Analysis

 

12.  Market Forecast and Opportunity Analysis

 

13.  Concluding Remarks

 

14.  Executive Insights

 

15.  Appendix 1:  Tabulated Data

 

16.  Appendix 2: List Of Companies And Organization

 

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/subcutaneous-biologics-delivery/314.html

Other Recent Offerings

1.     Global Autoinjectors Market (3rd Edition), 2020-2030

2.     Prefilled Syringes Market (5th Edition), 2020-2030

3.     Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030

4.     Large Volume Wearable Injectors Market (4th Edition), 2018-2030

 

About Roots Analysis

Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com

 

Contact Details

Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/

Comments

Post a Comment

Popular posts from this blog

The microbial contract biomanufacturing market is growing at a CAGR of 8.7%, claims {Roots Analysis}

    The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment     London   Roots Analysis has announced the addition of the “ Microbial Contract Biomanufacturing Market, 2020-2030 ” report to its list of offerings.   Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various...
Read more

Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030 by Roots Analysis

  Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030 .”   The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing §   Elaborate profiles of some of the key...
Read more

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more